Are the frequencies and characteristics of “MS Hug” different for people with MS (PwMS) of different characteristics, such as age, sex or disability level? Are some MS Hug treatments more effective than others in specific PwMS?
What can people with MS following specific diets expect in terms of fatigue improvement, and is this affected by personal characteristics, like age, disability level, or initial fatigue level? Can combining diet with exercise help reduce fatigue further?
What are the best strategies for preventing falls in people with MS based on specific causes, such as dizziness or weakness? Are combinations of some strategies more effective than single strategies alone?
Does the effectiveness of the COVID-19 vaccines differ based on duration of treatment with a B-cell depleting drug?
Do the COVID-19 vaccines have specific effects on people with MS that haven’t been observed with other types of vaccines? If so, what is responsible for these differences?
Should people with MS on B-cell depleting therapies be tested for antibodies after being fully vaccinated as part of standard clinical care?
Could the COVID-19 vaccine trigger the onset of MS in those who are already at a higher risk of developing it, such as direct relatives of people diagnosed with MS?
Does the COVID-19 vaccine have the potential to help resolve residual neurological symptoms in people with MS, based on evidence of improvement in fatigue and cognitive issues seen in COVID long haulers?